Callan Family Office LLC Makes New Investment in The Clorox Company $CLX

Key Points

• Callan Family Office LLC has made a new investment in The Clorox Company, acquiring 2,638 shares valued at approximately $317,000 in the second quarter.
• Several institutional investors also increased their positions in Clorox, with a significant 94.8% boost from Shell Asset Management Co. and a total of 78.53% institutional ownership.
• Brokerages have issued revised price targets for Clorox, with Wells Fargo lowering their target from $130 to $125 and Deutsche Bank decreasing it from $135 to $128.

Callan Family Office LLC purchased a new stake in The Clorox Company (NYSE:CLX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,638 shares of the company's stock, valued at approximately $317,000.

Other institutional investors have also recently made changes to their positions in the company. Leo Wealth LLC bought a new stake in shares of Clorox during the 2nd quarter valued at about $285,000. Vontobel Holding Ltd. boosted its position in shares of Clorox by 0.9% during the 2nd quarter. Vontobel Holding Ltd. now owns 26,365 shares of the company's stock valued at $3,166,000 after purchasing an additional 246 shares in the last quarter. Clear Creek Financial Management LLC bought a new stake in shares of Clorox during the 2nd quarter valued at about $207,000. Hall Capital Management Co. Inc. boosted its position in shares of Clorox by 4.4% during the 2nd quarter. Hall Capital Management Co. Inc. now owns 2,851 shares of the company's stock valued at $342,000 after purchasing an additional 120 shares in the last quarter. Finally, Shell Asset Management Co. boosted its position in shares of Clorox by 94.8% during the 2nd quarter. Shell Asset Management Co. now owns 16,079 shares of the company's stock valued at $1,931,000 after purchasing an additional 7,824 shares in the last quarter. Institutional investors own 78.53% of the company's stock.

Insiders Place Their Bets

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer directly owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.63% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CLX. Wells Fargo & Company cut their price target on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a report on Thursday, September 25th. Barclays cut their price target on Clorox from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Tuesday, September 30th. Deutsche Bank Aktiengesellschaft cut their price target on Clorox from $135.00 to $128.00 and set a "hold" rating on the stock in a report on Monday. Citigroup cut their price target on Clorox from $135.00 to $130.00 and set a "neutral" rating on the stock in a report on Wednesday, October 8th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Clorox in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average price target of $131.64.

Clorox Stock Performance

Shares of CLX opened at $118.56 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The company has a market capitalization of $14.44 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 0.99 and a beta of 0.52. The stock has a 50 day moving average of $121.88 and a 200 day moving average of $128.27. The Clorox Company has a 12 month low of $116.53 and a 12 month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.Clorox's revenue was up 4.5% on a year-over-year basis. During the same period last year, the business posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, sell-side analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox's dividend payout ratio is 76.07%.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.